MD Anderson experts say greater understanding of the immune response to tumors is necessary to spread the success of the cancer treatment beyond those patients currently enjoying powerful, long-term responses.
A cost-effectiveness analysis led by MD Anderson researchers predicts the price of newly approved therapies to treat people infected with the hepatitis C virus will place a tremendous economic burden on the country’s health care system.
Even in late stages, head and neck cancers such as oropharyngeal cancer can be cured. Proton therapy can strategically pinpoint the disease, save the surrounding tissue and allow patients to avoid debilitating side effects brought on by traditional radiation.
Scientists at MD Anderson have found a cell-signaling pathway can be manipulated to regulate the fuel that feeds all cells, including those in tumors. The findings may open up a new avenue for cancer therapy.
MD Anderson is teaming with Astellas to research and develop a monoclonal antibody to treat acute myeloid leukemia. ORBIT is a centralized organization that guides, informs and executes the preclinical and clinical development of monoclonal antibodies.